Human T-lymphotropic virus type II and neurological disease

Detalhes bibliográficos
Autor(a) principal: Araújo, Abelardo
Data de Publicação: 2004
Outros Autores: Hall, William W.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/33614
Resumo: 2020-06-21
id CRUZ_8c8157060a8f03e6ce9f8e1d18e337d7
oai_identifier_str oai:www.arca.fiocruz.br:icict/33614
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Araújo, AbelardoHall, William W.2019-06-21T12:19:53Z2019-06-21T12:19:53Z2004ARAUJO, Abelardo; HALL, William W. Human T-lymphotropic virus type II and neurological disease. Annals of Neurology, v. 56, n. 1, p. 10-19, July 2004.0364-5134https://www.arca.fiocruz.br/handle/icict/3361410.1002/ana.201261531-8249engWileyHuman T-lymphotropic virus type II and neurological diseaseinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article2020-06-21Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / University College Dublin. Conway Institute of Biomolecular and Biomedical Research. Department of Medical Microbiology. Dublin, Ireland.University College Dublin. Conway Institute of Biomolecular and Biomedical Research. Department of Medical Microbiology. Dublin, Ireland.Human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II) are closely related retroviruses with similar bio-logical properties and common modes of transmission. HTLV-I infection is endemic in well-defined geographic regions,and it is estimated that some 20 million individuals are infected worldwide. Although most infected individuals areasymptomatic carriers, some 2 to 5% will develop a chronic encephalomyelopathy, HTLV-I–associated myelopathy/tropical spastic paraparesis (HAM/TSP). In contrast with HTLV-I, the role of HTLV-II in the development of neuro-logical disorders is much less clear. HTLV-II is endemic in many native Amerindian groups and epidemic in injectingdrug users (IDUs) worldwide. To evaluate the role of HTLV-II in neurological disease, we have critically reviewed allreported cases of HTLV-II–associated disorders. This has confirmed that although rare infection is associated with adisorder clinically similar or identical to HAM/TSP. However, most reports that have attributed infection to a range ofother neurological disorders are difficult to evaluate in that in many cases either the association appears to be fortuitousor the presentations were confounded by a background of concomitant human immunodeficiency virus–1 infectionand/or active IDU. In view of the many HTLV-II–infected individuals in urban areas of North America and Europe,neurologists should be aware of the potential clinical consequences of this infection.HTLV-IHTLV-IINeurological diseaseinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1748https://www.arca.fiocruz.br/bitstream/icict/33614/1/license.txt8a4605be74aa9ea9d79846c1fba20a33MD51ORIGINALAraujo_Abelardo_etal_INI_2004.pdfAraujo_Abelardo_etal_INI_2004.pdfapplication/pdf94087https://www.arca.fiocruz.br/bitstream/icict/33614/2/Araujo_Abelardo_etal_INI_2004.pdf62b5fd1e5b298f95f8820ed135d93a63MD52ve_Araujo_Abelardo_etal_INI_2004.pdfve_Araujo_Abelardo_etal_INI_2004.pdfapplication/pdf94087https://www.arca.fiocruz.br/bitstream/icict/33614/3/ve_Araujo_Abelardo_etal_INI_2004.pdf62b5fd1e5b298f95f8820ed135d93a63MD53TEXTAraujo_Abelardo_etal_INI_2004.pdf.txtAraujo_Abelardo_etal_INI_2004.pdf.txtExtracted texttext/plain51285https://www.arca.fiocruz.br/bitstream/icict/33614/4/Araujo_Abelardo_etal_INI_2004.pdf.txt4f045eddcae15f396155b0fc219ff96aMD54ve_Araujo_Abelardo_etal_INI_2004.pdf.txtve_Araujo_Abelardo_etal_INI_2004.pdf.txtExtracted texttext/plain51285https://www.arca.fiocruz.br/bitstream/icict/33614/5/ve_Araujo_Abelardo_etal_INI_2004.pdf.txt4f045eddcae15f396155b0fc219ff96aMD55icict/336142021-03-24 16:32:33.343oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-03-24T19:32:33Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Human T-lymphotropic virus type II and neurological disease
title Human T-lymphotropic virus type II and neurological disease
spellingShingle Human T-lymphotropic virus type II and neurological disease
Araújo, Abelardo
HTLV-I
HTLV-II
Neurological disease
title_short Human T-lymphotropic virus type II and neurological disease
title_full Human T-lymphotropic virus type II and neurological disease
title_fullStr Human T-lymphotropic virus type II and neurological disease
title_full_unstemmed Human T-lymphotropic virus type II and neurological disease
title_sort Human T-lymphotropic virus type II and neurological disease
author Araújo, Abelardo
author_facet Araújo, Abelardo
Hall, William W.
author_role author
author2 Hall, William W.
author2_role author
dc.contributor.author.fl_str_mv Araújo, Abelardo
Hall, William W.
dc.subject.en.pt_BR.fl_str_mv HTLV-I
HTLV-II
Neurological disease
topic HTLV-I
HTLV-II
Neurological disease
description 2020-06-21
publishDate 2004
dc.date.issued.fl_str_mv 2004
dc.date.accessioned.fl_str_mv 2019-06-21T12:19:53Z
dc.date.available.fl_str_mv 2019-06-21T12:19:53Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv ARAUJO, Abelardo; HALL, William W. Human T-lymphotropic virus type II and neurological disease. Annals of Neurology, v. 56, n. 1, p. 10-19, July 2004.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/33614
dc.identifier.issn.pt_BR.fl_str_mv 0364-5134
dc.identifier.doi.none.fl_str_mv 10.1002/ana.20126
dc.identifier.eissn.none.fl_str_mv 1531-8249
identifier_str_mv ARAUJO, Abelardo; HALL, William W. Human T-lymphotropic virus type II and neurological disease. Annals of Neurology, v. 56, n. 1, p. 10-19, July 2004.
0364-5134
10.1002/ana.20126
1531-8249
url https://www.arca.fiocruz.br/handle/icict/33614
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/33614/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/33614/2/Araujo_Abelardo_etal_INI_2004.pdf
https://www.arca.fiocruz.br/bitstream/icict/33614/3/ve_Araujo_Abelardo_etal_INI_2004.pdf
https://www.arca.fiocruz.br/bitstream/icict/33614/4/Araujo_Abelardo_etal_INI_2004.pdf.txt
https://www.arca.fiocruz.br/bitstream/icict/33614/5/ve_Araujo_Abelardo_etal_INI_2004.pdf.txt
bitstream.checksum.fl_str_mv 8a4605be74aa9ea9d79846c1fba20a33
62b5fd1e5b298f95f8820ed135d93a63
62b5fd1e5b298f95f8820ed135d93a63
4f045eddcae15f396155b0fc219ff96a
4f045eddcae15f396155b0fc219ff96a
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813009284665966592

Registros relacionados